Muutke küpsiste eelistusi

Progress in Molecular Biology and Translational Science: Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics Part A, Volume 162 [Kõva köide]

Volume editor (Ocean University of China, Qingdao, China)
Teised raamatud teemal:
Progress in Molecular Biology and Translational Science: Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics Part A, Volume 162Suurem pilt
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9780128177389.html
Märksõnad:

Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A, Volume 162 in the Progress in Molecular Biology and Translational Science series provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include Glycan-based Biomarkers for Diagnosis of Cancers and Other Diseases: Past, Present and Future, Desialylation in Diseases and its Application in Diagnostic and Therapeutic Development, Proteoglycans as Miscommunication Biomarkers for Cancer Diagnosis, Fucosylation in Cancer Biology and Its Clinical Applications, Retrospective Analysis of Glycan-Related Biomarkers Based on Clinical Laboratory Data in Two Medical Centers, and many related topics.

  • Includes comprehensive coverage of molecular biology
  • Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided
  • Contains contributions from renowned experts in the field
Contributors xiii
Preface xvii
1 Glycan-based biomarkers for diagnosis of cancers and other diseases: Past, present, and future 1(24)
Minghui Hu
Ying Lan
Alexander Lu
Xuexiao Ma
Lijuan Zhang
1 Introduction
2(4)
2 The milestones in glycan-, glycoprotein-, and glycated protein-based biomarker discovery
6(4)
3 Clinically used serum glucose-, glycan-, or glycoprotein-based biomarkers
10(2)
4 Serum glycoprotein-derived N- and 0-linked glycans as cancer biomarkers
12(4)
5 Discussions and conclusions
16(2)
Acknowledgment
18(1)
Conflict of interest
18(1)
References
18(7)
2 Desialylation in physiological and pathological processes: New target for diagnostic and therapeutic development 25(34)
Mohui Wei
Peng George Wang
1 Introduction
26(5)
2 Desialylation in physiology
31(7)
3 Desialylation in pathology
38(6)
4 Diagnostic and therapeutic development targeting on desialylation
44(3)
5 Chemical desialylation
47(3)
6 Conclusions and perspectives
50(1)
References
50(9)
3 Proteoglycans as miscommunication biomarkers for cancer diagnosis 59(34)
Lingling Xu
Limin Tang
Lijuan Zhang
1 Introduction
60(2)
2 GAG-based cancer biomarkers
62(3)
3 Proteoglycan-based cancer biomarkers
65(11)
4 GAG biosynthesis, degradation, and modifying enzymes
76(4)
5 Concluding remarks
80(1)
Acknowledgments
81(1)
Conflicts of interest
81(1)
References
81(12)
4 Fucosylation in cancer biology and its clinical applications 93(28)
Ming Shan
Dandan Yang
Huaiqian Dou
Lijuan Zhang
1 Introduction
94(1)
2 Fucosylation
95(1)
3 Aberrant fucosylation in cancer
96(7)
4 Role of fucosylation in carcinogenesis
103(4)
5 Clinical potential and applications of changed fucosylation in cancer diagnosis and treatment
107(4)
6 Conclusion and future perspectives
111(1)
Acknowledgment
112(1)
References
112(9)
5 The sensitivity and specificity of serum glycan-based biomarkers for cancer detection 121(20)
Yang Tang
Yidi Cui
Shufeng Zhang
Lijuan Zhang
1 Introduction
122(1)
2 Clinically used cancer biomarkers developed based on hybridoma technology
123(5)
3 Other clinically used cancer biomarkers
128(4)
4 Conclusions and future perspectives
132(2)
Acknowledgments
134(1)
Conflicts of interest
134(1)
References
134(7)
6 Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past 6 years 141(24)
Meng Zhang
Huaiqian Dou
Dandan Yang
Ming Shan
Xiulian Li
Cui Hao
Yiran Zhang
Pengjiao Zeng
Yanli He
Yong Liu
Jing Fu
Wei Wang
Minghui Hu
Hui Li
Qingwu Tian
Shuhe Lei
Lijuan Zhang
1 Introduction
142(2)
2 Methods
144(1)
3 Results
145(14)
4 Discussions and conclusions
159(1)
Acknowledgments
160(1)
Conflicts of interest
160(1)
References
160(5)
7 Serum SCCA levels in patients suffering cancers or other diseases 165(12)
Dandan Yang
Jun Wang
Lijuan Zhang
1 Introduction
166(1)
2 Serum SCCA level measurement
167(1)
3 Serum SCCA levels in 39 human diseases and in healthy controls
168(4)
4 Discussions and conclusions
172(1)
Acknowledgments
173(1)
Conflicts of interest
173(1)
References
173(4)
8 Increased serum CA724 levels in patients suffering gout vs cancers 177(10)
Yiran Zhang
Meng Zhang
Xueshan Bai
Changgui Li
Lijuan Zhang
1 Introduction
178(1)
2 Determination of serum CA724 levels
179(1)
3 Serum CA724 levels in 37 different types of human diseases
180(3)
4 Discussions and conclusions
183(1)
Acknowledgments
184(1)
Conflicts of interest
184(1)
References
184(3)
9 Serum CA50 levels in patients with cancers and other diseases 187(12)
Ming Shan
Qingwu Tian
Lijuan Zhang
1 Introduction
188(2)
2 Serum CA50 concentration measurement
190(1)
3 Serum CA50 concentrations in 14 different types of human diseases
191(4)
4 Discussions and conclusions
195(1)
Acknowledgments
196(1)
Conflicts of interest
196(1)
References
196(3)
10 Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases 199(14)
Yanli He
Haijun Lu
Lijuan Zhang
1 Introduction
200(2)
2 Determination of serum AFP concentration/serum AFP activity measurement
202(1)
3 Serum AFP levels in 47 different types of diseases
203(4)
4 Discussions and conclusions
207(2)
Acknowledgments
209(1)
Conflicts of interest
209(1)
References
209(4)
11 Serum CEA levels in 49 different types of cancer and noncancer diseases 213(16)
Cui Hao
Guoqing Zhang
Lijuan Zhang
1 Introduction
214(3)
2 Serum CEA level measurement
217(1)
3 Serum CEA activities in 49 human diseases
218(4)
4 Discussions and conclusions
222(2)
Acknowledgment
224(1)
Conflict of interest
224(1)
Reference
224(5)
12 CA242 as a biomarker for pancreatic cancer and other diseases 229(12)
Huaiqian Dou
Guirong Sun
Lijuan Zhang
1 Introduction
230(2)
2 Serum CA242 measurement
232(1)
3 Serum CA242 levels in 27 diseases
232(3)
4 Conclusion and discussion
235(2)
Acknowledgment
237(1)
Conflict of interest
237(1)
References
237(4)
13 Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers 241(12)
Meng Zhang
Yiran Zhang
Jing Fu
Lijuan Zhang
1 Introduction
242(1)
2 Determination of serum CA125 levels
243(1)
3 Serum CA125 levels in 40 different types of human diseases
244(3)
4 Conclusions and discussions
247(3)
Acknowledgments
250(1)
Conflict of interest
250(1)
References
250(3)
14 Serum CA199 levels are significantly increased in patients suffering from liver, lung, and other diseases 253(12)
Pengjiao Zeng
Hui Li
Yulong Chen
Haitao Pei
Lijuan Zhang
1 Introduction
254(2)
2 Serum CA199-level measurement
256(1)
3 Serum CA199 levels in 47 human diseases and in healthy controls
257(4)
4 Discussions and conclusions
261(1)
Acknowledgments
262(1)
Conflicts of interest
262(1)
References
262(3)
15 Serum CA153 as biomarker for cancer and noncancer diseases 265(12)
Xiulian Li
Yan Xu
Lijuan Zhang
1 Introduction
266(1)
2 Serum CA153 measurement
267(1)
3 Serum CA153 levels in 30 different types of diseases
268(4)
4 Discussions and conclusions
272(1)
Acknowledgments
273(1)
Conflicts of interest
273(1)
References
273(4)
16 Fasting blood glucose levels in patients with different types of diseases 277(16)
Qinghua Zhang
Gang Zhao
Nailong Yang
Lijuan Zhang
1 Introduction
278(2)
2 FBG measurement
280(1)
3 FBG levels in 64 different types of diseases
281(4)
4 Discussions and conclusions
285(3)
Acknowledgments
288(1)
Conflicts of interest
288(1)
References
288(5)
17 HbA1c: High in acute cerebral infarction and low in brain trauma 293(14)
Zhifeng Jiang
Jigang Wang
Peng Zhao
Lijuan Zhang
Yunliang Guo
1 Introduction
294(2)
2 Methods for HbA1c measurement
296(1)
3 HbA1c levels in 36 different types of diseases
297(4)
4 Discussions and conclusions
301(2)
Acknowledgment
303(1)
Conflict of interest
303(1)
References
303(4)
18 Glycated albumin level is significantly decreased in patients suffering nephrotic syndrome 307(14)
Zhe Wang
Guangqun Xing
Lijuan Zhang
1 Introduction
308(1)
2 Methods for GA measurement
309(1)
3 GA levels in 57 different types of diseases
310(4)
4 Discussions and conclusions
314(2)
Acknowledgment
316(1)
Conflict of interest
316(1)
References
316(5)
19 Glycated serum proteins: High in pancreatic cancer and low in preeclampsia 321(14)
Xueling Wang
Rui Zhang
Lijuan Zhang
Zibin Tian
1 Introduction
322(1)
2 Methods for GSP measurement
323(1)
3 GSP levels in 61 different types of diseases
324(5)
4 Discussions and conclusions
329(1)
Acknowledgments
330(1)
Conflicts of interest
331(1)
References
331(4)
20 The serum SA levels are significantly increased in sepsis but decreased in cirrhosis 335(14)
Xiaodan Huang
Qin Yao
Lijuan Zhang
Zibin Tian
1 Introduction
336(2)
2 Serum/plasma SA concentration measurement
338(1)
3 Serum SA levels in 64 different types of diseases
339(4)
4 Discussions and conclusions
343(2)
Acknowledgment
345(1)
Conflict of interest
345(1)
References
346(3)
21 Serum α-L-fucosidase activities are significantly increased in patients with preeclampsia 349(14)
Meng Zhang
Lin Wang
Haiping Zhang
Juan Cong
Lijuan Zhang
1 Introduction
350(3)
2 Serum α-L-fucosidase activity measurement
353(1)
3 Serum α-L-fucosidase activities in 64 human diseases
354(5)
4 Discussions and conclusions
359(1)
Acknowledgment
360(1)
Conflict of interest
360(1)
References
360(3)
22 Glucuronidated bilirubin: Significantly increased in hepatic encephalopathy 363(14)
Limin Tang
Meng Zhang
Xiulian Li
Lijuan Zhang
1 Introduction
364(2)
2 Serum bilirubin measurement
366(1)
3 Serum direct bilirubin levels in 38 different types of human diseases and healthy controls
367(5)
4 Discussions and conclusions
372(1)
Acknowledgment
373(1)
Conflict of interest
373(1)
References
373(4)
23 Serum PSA levels in patients with prostate cancer and other 33 different types of diseases 377(14)
Yanyun Gao
Meng Zhang
Xiulian Li
Pengjiao Zeng
Peitao Wang
Lijuan Zhang
1 Introduction
378(1)
2 Determination of serum PSA levels
379(1)
3 Serum PSA levels in 33 different types of human diseases and healthy controls
380(6)
4 Discussions and conclusions
386(2)
Acknowledgments
388(1)
Conflicts of interest
388(1)
References
388(3)
Index 391
Lijuan Zhang is a Professor of Translational Medicine at Ocean University of China. She completed her doctorates of biochemistry and molecular genetics at University of Alabama at Birmingham in 1995. Before then, she was a Fogarty International Fellow at NIH for three years studying glycan-based cancer biomarkers. She worked as post-doctorate fellow and research associate at both MIT and Harvard Medical School from 1995-2002. She joined the faculty of the Department of Pathology & Immunology at Washington University in St. Louis in 2002 as a tenure-tracked Assistant Professor. Her research had been focused on the biosynthesis, structures, and biological functions of glycans since 1985. Now her work is on translational aspects of glycans as biomarkers and therapeutics. She has over 60 peer reviewed publications. She edited and published a book entitled Glycosaminoglycans in Development, Health, and Diseases” with the contributions of top scientists worldwide in 2010 by Elsevier.